By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

The sleep disorder also appears to have direct effects on brain health, a new study shows. People with sleep apnea appear to ...

was cleared to treat moderate to severe forms of the sleep condition in people with obesity. It should be used with a reduced ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Obstructive sleep apnea is when a person stops ... 56% had no sleep problems, 28% had mild sleep problems and 16% had moderate to severe sleep problems. Researchers also measured oxygen levels ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in ... with Zepbound achieved remission or mild sleep apnea with resolution of symptoms compared ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...